Xeomin [incobotulinumtoxinA, Merz Aesthetics] and Botox [onabotulinumtoxinA, Allergan] were equally efficacious at one month, the primary efficacy endpoint, in the treatment of moderate to severe glabellar facial lines, according to a study sponsored by Merz North America, the maker of Xeomin (incobotulinumtoxinA) and published November 2015 in Dermatologic Surgery.
“Similar efficacy and tolerability profiles were observed through 4 months after treatment,” according to the study’s abstract.
In this first randomized, prospective, double-blinded, parallel-group study to compare the neurotoxins head to head, researchers studied 250 women, 18 to 50 years of age. They used the recommended single 20-unit dose in both treatment groups.
Patient satisfaction ratings and tolerability were favorable and similar in both groups, according to the study.
“Xeomin is an excellent product with limited name recognition. Patients who are seeking an alternative product that is competitively priced often consider switching neuromodulators,” says Mary P. Lupo, M.D., a New Orleans dermatologist who has been on the advisory boards for Allergan, Galderma and Merz. Dr. Lupo was in the pivotal study for the FDA approval for Botox for crow's feet.
From Earlier This Year: Botox vs Xeomin: Study results are in
